Drug Discovery, Clinical Trials, and Biobanking

Vocabulary practice flashcards covering drug discovery stages, preclinical studies, clinical trial phases (0–IV), regulatory criteria, biobanking principles, and personalized medicine.

Random Screening

A drug discovery approach where natural products (such as morphine, digitalis, artemisinin, quinidine, and atropine) or randomly synthesized chemical entities (such as barbiturates and chlorpromazine) are tested for pharmacological activity.

Serendipity (in Drug Discovery)

The identification of new drugs or novel therapeutic applications through chance observation or unexpected side effects, such as penicillin, methotrexate in psoriasis, sildenafil in impotence, and lignocaine as an antiarrhythmic.

Rational Drug Designing

A structured drug discovery strategy using either a compound-centered approach (modifying chemical structures, like developing beta blockers from propranolol) or a receptor-based approach relying on knowledge of specific biological targets.

Drug Target

A specific biological molecule—usually a protein (receptor, enzyme, or transport protein) or DNA—involved in a disease process whose function is modulated by a drug.

Active Substance Sources

The biological or chemical origins of therapeutic entities, which include plants (digoxin, atropine), human cells (urokinase), animal tissue (heparin), gene technology (human insulin), microbial cultures (penicillin), and synthetic chemicals (piroxicam, ziprasidone).

Molecular Modulation

The chemical optimization of hit compounds to increase their potency, selectivity, and metabolic stability while eliminating undesirable features such as high molecular weight, excessive polarity, and toxic groups.

Preclinical Development

Laboratory studies conducted in isolated tissues or animal models to assess a compound's pharmacology, pharmacokinetics (ADME), adverse effects, toxicology, mutagenicity, carcinogenicity, and reproductive safety before human administration.

Toxicological studies

to determine the maximum non-toxic dose of the drug

Mutagenicity Study

A toxicological assessment conducted during preclinical testing to identify compounds that can cause genetic damage.

Carcinogenicity Study

A preclinical evaluation to identify compounds that can induce cancer, typically required if the drug will be administered to humans for more than $1\text{ year}$, resembles a known carcinogen, or tests positive for mutagenicity.

Investigational New Drug (IND) Application

A regulatory submission to the FDA detailing preclinical animal safety, drug composition, manufacturing data, and proposed clinical protocols before human trials can begin.

Center for Drug Evaluation and Research (CDER)

The FDA division responsible for evaluating new brand-name and generic drugs prior to commercial sale to ensure that their clinical benefits outweigh known risks.

Phase 0 Clinical Trial

An exploratory IND trial involving human micro-dosing (administering a few small doses to very few individuals) to evaluate pharmacokinetics, drug mechanism of action, or tumor penetration before Phase I.

Phase I Clinical Trial

First-in-human safety and tolerability studies typically conducted on $20-80$ (or $25-50$) healthy volunteers to establish the dose-response curve, determine the maximum tolerated dose (MTD), and assess pharmacokinetics.

Single Ascending Dose (SAD)

A Phase I clinical trial design where small cohorts of subjects receive a single dose of the test drug, escalating to higher doses in subsequent cohorts if safety and tolerability are demonstrated.

Multiple Ascending Dose (MAD)

A Phase I clinical trial design where subjects receive multiple scheduled doses of the drug to observe accumulation, pharmacokinetics, and safety at ascending dose levels.

Phase II Clinical Trial

Controlled clinical studies conducted on $100-300$ patients with the target disease to evaluate drug efficacy, determine therapeutic dosing, assess short-term risks, and establish proof of concept.

Placebo

An inert substance, identical in appearance and administration to the active drug candidate, given as a comparator treatment in controlled clinical trials.

Blinding

A clinical trial procedure designed to keep participants, investigators, or both unaware of whether the participant is receiving the active experimental drug or a comparator/placebo.

Phase III Clinical Trial

Large-scale, controlled, double-blind trials conducted on $1{,}000-3{,}000$ patients to confirm efficacy and safety across diverse populations, test dosages and drug combinations, and generate data for physician labeling.

New Drug Application (NDA)

A formal, comprehensive electronic submission to the FDA following successful Phase I–III trials that includes all chemical, preclinical, clinical, and manufacturing data seeking marketing approval.

Phase IV Clinical Trial

Post-marketing surveillance studies conducted after regulatory approval to detect rare, long-term adverse events, evaluate broader population outcomes, and maintain pharmacovigilance.

Pharmacovigilance

The pharmacological science relating to the collection, detection, assessment, monitoring, and prevention of adverse effects associated with pharmaceutical products.

Biorepository

A biological materials repository that collects, processes, stores, and distributes biospecimens from various living organisms (including animals and humans) to support scientific investigation.

Biobank

A specialized type of biorepository that collects, processes, stores, and distributes human biological samples along with their associated clinical and demographic data for research purposes.

Biospecimen

Biological human material preserved for research, including blood, plasma, serum, red/white blood cells, buffy coat, DNA, RNA, protein, cell lines, urine, CSF, synovial fluid, amniotic fluid, and frozen or FFPE tissues.

Formalin-Fixed Paraffin-Embedded (FFPE)

A standard laboratory method for preserving tissue biopsy specimens by chemical fixation in formalin followed by embedding in paraffin wax blocks for long-term room-temperature storage.

Biobank Storage Conditions

The preservation parameters used for biospecimens, specifically $-80\,^\circ\text{C}$ freezers for blood, plasma, serum, and DNA, and liquid nitrogen freezers at $-196\,^\circ\text{C}$ for tissues and cell lines.

Disease-Specific Biobank

A biobank focused on collecting pathological tissue samples, fluids, and medical data exclusively from patients diagnosed with a particular condition (such as breast cancer or prostate cancer).

Personalized Medicine

The tailoring of medical treatment to individual characteristics, needs, and preferences across all stages of care (often defined as 'the right patient with the right dose of the right drug at the right time').